<DOC>
	<DOC>NCT02315638</DOC>
	<brief_summary>This is a long-term safety follow-up protocol for subjects who received TT-034 under the B2801001 protocol and consists of monitoring for at least 4.5 years.</brief_summary>
	<brief_title>Long-Term Follow-Up Safety Monitoring of Patients Dosed in the First-in-Man Phase I/II Study of TT-034.</brief_title>
	<detailed_description>The main purpose of this follow-up study is to detect events suggestive of delayed adverse effects of the study drug by review of clinical histories and discussion with subjects to identify/elicit significant medical events, including but not limited to hematologic, malignant, autoimmune, neurologic, and hepatic events.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Prior enrollment in Study B2801001 and dosing with TT034 An informed consent form for this study signed and dated by the subject or a legally acceptable representative There are no specific exclusion criteria for this followup study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Adeno-associated viral vectors</keyword>
	<keyword>Adeno-associated virus</keyword>
	<keyword>AAV</keyword>
	<keyword>AAV8</keyword>
	<keyword>ddRNAi</keyword>
	<keyword>shRNA</keyword>
	<keyword>RNAi</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>CHC</keyword>
	<keyword>Genotype 1</keyword>
</DOC>